The vulnerability of the global vaccine supply chain was laid bare during the early years of the pandemic, leaving much of the African continent at the mercy of international export priorities. Biovac, a South African biotechnology firm, is positioning itself as a cornerstone of a more resilient regional system. With $108 million in new financing from the European Investment Bank, the European Commission, and the International Finance Corporation, the company is set to scale its manufacturing capabilities significantly.
The investment will fund a new facility in Cape Town designed to produce up to 400 million vaccine doses per year. This expansion is less about the immediate demands of a single virus and more about establishing a permanent, high-capacity infrastructure for both routine immunizations and future pandemic responses. By localizing the "fill and finish" process and moving toward end-to-end production, the project aims to reduce the continent’s reliance on imported medical products.
This move reflects a broader shift in global health strategy toward distributed manufacturing. Rather than relying on a handful of massive hubs in Europe, Asia, or North America, the goal is to create regional centers of excellence capable of serving their own populations. For Biovac, the backing of major international financial institutions provides the necessary capital to transform Cape Town into one of these vital nodes in the global health network.
With reporting from Endpoints News.
Source · Endpoints News
